Gentry Private Wealth LLC Has $444,000 Stake in Kenvue Inc. (NYSE:KVUE)

Gentry Private Wealth LLC trimmed its stake in Kenvue Inc. (NYSE:KVUE) by 3.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,211 shares of the company’s stock after selling 686 shares during the period. Gentry Private Wealth LLC’s holdings in Kenvue were worth $444,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of KVUE. Van ECK Associates Corp grew its position in Kenvue by 110.9% in the 2nd quarter. Van ECK Associates Corp now owns 20,510,427 shares of the company’s stock worth $372,880,000 after purchasing an additional 10,783,258 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Kenvue by 21.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 43,444,085 shares of the company’s stock valued at $789,813,000 after acquiring an additional 7,546,362 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Kenvue by 8.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock valued at $2,011,832,000 after acquiring an additional 7,115,374 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Kenvue by 20.7% during the 2nd quarter. American Century Companies Inc. now owns 27,382,644 shares of the company’s stock valued at $497,816,000 after acquiring an additional 4,700,697 shares in the last quarter. Finally, M&G PLC boosted its position in shares of Kenvue by 538.0% during the 3rd quarter. M&G PLC now owns 4,341,172 shares of the company’s stock valued at $99,847,000 after acquiring an additional 3,660,730 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Trading Down 0.0 %

Shares of NYSE KVUE opened at $24.08 on Friday. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.31. The company has a market cap of $46.17 billion, a PE ratio of 43.78, a P/E/G ratio of 2.19 and a beta of 1.36. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The company has a 50-day moving average of $22.84 and a two-hundred day moving average of $20.86.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company had revenue of $3.90 billion during the quarter, compared to the consensus estimate of $3.92 billion. During the same period in the previous year, the firm posted $0.31 earnings per share. The company’s revenue was down .4% on a year-over-year basis. As a group, equities analysts expect that Kenvue Inc. will post 1.07 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th will be paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.41%. The ex-dividend date is Wednesday, November 13th. Kenvue’s dividend payout ratio is presently 149.09%.

Analysts Set New Price Targets

Several brokerages have recently weighed in on KVUE. Bank of America lifted their target price on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. JPMorgan Chase & Co. lifted their target price on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. UBS Group lifted their target price on shares of Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. Piper Sandler boosted their price target on shares of Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research report on Monday, September 23rd. Finally, Jefferies Financial Group started coverage on shares of Kenvue in a research report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price target on the stock. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Kenvue presently has an average rating of “Hold” and a consensus price target of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.